IP Library Granted Patent US 8,461,337
Granted Patent B2
US 8,461,337 · App. 12/316,846 · Granted Jun 11, 2013

Sinomenine derivatives and processes for their synthesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,461,337
App. No.
12/316,846
Granted
Jun 11, 2013
Kind
B2
Abstract

The invention generally provides processes and intermediate compounds useful for the production of sinomenine derivatives. In particular, the process may encompass synthetic routes for the production of (+)-sinomenine derivatives and their intermediates.

Claims (43)

1. A compound having a Formula (I):

wherein:

R 1 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 2 and R 3 and are independently selected from the group consisting of hydrogen, halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 4 is independently selected from the group consisting of halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═NOH, ═S, ═CHR 5a , and —O(CH 2 ) 2 O—;

R 5a is selected from the group consisting of hydrogen, halogen, hydrocarbyl, and substituted hydrocarbyl;

R 7 is selected from the group consisting of hydrogen and OR 7a ;

R 7a is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 8 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 9 and R 10 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 9 and R 10 together may form a group selected from the group consisting of ═O and ═S;

R 11 and R 12 are independently selected from the group consisting of hydrogen, OH, halogen, hydrocarbyl, and substituted hydrocarbyl;

Y is selected from the group consisting of alkyl, substituted alkyl, carbonyl, and alkyl carbonyl; and,

m is an integer from 0 to 8,

and further wherein C9, C13 and C14 reference carbon numbers 9, 13 and 14, respectively, of Formula (I).

2. The compound of claim 1 , wherein:

R 1 is selected from the group consisting of an alkyl group having from 1 to 8 carbon atoms, a vinyl group, an aryl group, cyclopropyl, cyclobutyl, {—}CH(CF 3 ) 2 , {—}CH(CH 3 )CF 3 , {—}CH═CF 2 , and {—}CH 2 CF 3 ;

R 2 is selected from the group consisting of hydrogen and halogen;

R 4 is OH;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, and NH 2 ;

R 3 and R 8 -R 12 are each hydrogen;

Y is selected from the group consisting of {—}CH 2 {—} and {—}CO{—}; and

m is 0.

3. The compound of claim 1 , wherein the compound has a Formula (Ib):

wherein:

R 2 , R 4 , R 5 , R 6 and R 7 are as defined in claim 1 .

4. The compound of claim 1 , wherein the compound has a Formula (Ic):

wherein:

R 2 , R 4 , R 5 and R 6 are as defined in claim 1 .

5. The compound of claim 1 , wherein the compound is selected from the group consisting of:

6. The compound of claim 1 , wherein the optical activity of the compound is (−) or (+) and the configuration of C13, C14, and C9, respectively, is selected from the group consisting of RRS, RSS, SRR, and SSR.

7. A process for preparing a compound of Formula (I) of claim 1 , the process comprising contacting a reactant compound with a compound selected from the group consisting of R 1 YX and R 1 Y to form a the compound of Formula (I) according to the reaction scheme:

wherein:

R 2 and R 3 and are independently selected from the group consisting of hydrogen, halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 4 is independently selected from the group consisting of halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═NOH, ═S, ═CHR 5a , and —O(CH 2 ) 2 O—;

R 5a is selected from the group consisting of hydrogen, halogen, hydrocarbyl, and substituted hydrocarbyl;

R 1 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 9 and R 10 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 9 and R 10 together may form a group selected from the group consisting of ═O and ═S;

X is halogen;

Y is selected from the group consisting of alkyl, substituted alkyl, carbonyl, and alkyl carbonyl; and

m is an integer from 0 to 8.

8. The process of claim 7 , wherein the reaction is conducted in the presence of an aprotic solvent; the weight ratio of aprotic solvent to compound 3 is from about 1:1 to about 20:1; the weight ratio of the reactant compound to R 1 YX or R 1 Y is from about 1:1.1 to about 1:1.5; the reaction is conducted at a temperature ranging from about 20° C. to about 100° C.; the optical activity of the reactant compound and the compound of formula (I) is (−) or (+), and the configuration of C13, C14, and C9, respectively, is selected from the group consisting of RRS, RSS, SRR, and SSR.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2009
From: WANG, PETER X.; JIANG, TAO; CANTRELL, GARY L.; BERBERICH, DAVID W.; TRAWICK, BOBBY N.; LIAO, SUBO; BRANDT, JOHN D.
To: MALLINCKRODT INC.
Reel/Frame 022181/0952 →